Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors (NCT06358677)
A Phase II, Randomized, Double-Blind, Split-Face of Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to learn if using topical tretinoin will help patients with solid tumors who are experiencing an acneiform rash as a side effect of their treatment. Researchers will compare the use of tretinoin on one side of the face to the use of a placebo on the other side of the face to see if there is an impact.
Who can join: Review the eligibility criteria below.
Location: Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
📞 Contact the Study Coordinator
Phone: (801) 585-3453
Email: susan.sharry@hci.utah.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Solid Tumor
- A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors — Orlando, Florida
- Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS — Coral Gables, Florida
- Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM) — Baltimore, Maryland
- TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) — Los Angeles, California
- Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors — Anchorage, Alaska
- QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors — El Segundo, California
Explore by condition: All Metastatic Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.